Form 4: Teleflex CEO Liam Kelly Reports Stock and Option Awards

Liam Kelly, Chairman, President & CEO of Teleflex Inc., reports the acquisition of restricted stock units and stock options.

Summary

• On March 4, 2025, Liam Kelly, Chairman, President & CEO of Teleflex Inc., reported transactions involving Teleflex common stock and stock options.
• Kelly acquired 10,195 shares of common stock through a restricted stock unit award and holds 43,767.2911 shares directly.
• He also indirectly owns 19,316.653 shares through the Helen Kelly 2021 Irrevocable Trust.
• Additionally, Kelly acquired options to buy 71,983 shares of common stock at an exercise price of $130.79, which vest in three tranches starting March 4, 2026.
• The restricted stock units vest 25% annually starting March 4, 2026, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices and aligns management interests with shareholders. The vesting schedules promote long-term commitment.

Positives

• The grant of restricted stock units and stock options aligns the CEO's interests with those of the shareholders, incentivizing long-term value creation.
• The vesting schedules for both the restricted stock units and stock options encourage continued service and commitment from the CEO.

Risks

• The value of the stock options is dependent on the future performance of Teleflex's stock price, which is subject to market risks.
• The vesting of the restricted stock units and stock options is contingent upon the CEO's continued service, creating a potential risk if the CEO were to leave the company before the vesting dates.

Future Outlook

The document outlines future vesting dates for the granted stock options and restricted stock units, contingent on the reporting person's continued service to the issuer.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the compensation structure and equity ownership of key executives.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are standard components of executive compensation packages in the medical device industry.
• Vesting schedules are typically structured to incentivize long-term performance and retention, aligning with industry best practices.
• Companies like Medtronic, Stryker, and Johnson & Johnson also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation and alignment of interests.
• Employees: May influence morale and perception of fairness in compensation practices.
• Creditors: No direct impact.

Key Dates